Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system

Andreas Linninger, Grant A. Hartung, Benjamin P. Liu, Snezana Mirkov, Kevin Tangen, Rimas V. Lukas, Dusten Unruh, C. David James, Jann N Sarkaria, Craig Horbinski

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background. Among diffusely infiltrative gliomas in adults, 20%-30% contain a point mutation in isocitrate dehydrogenase 1 (IDH1mut), which increases production of D-2-hydroxyglutarate (D2HG). This is so efficient that D2HG often reaches 30 mM within IDH1mut gliomas. Yet, while up to 100 µM D2HG can be detected in the circulating cerebrospinal fluid of IDH1mut glioma patients, the exposure of nonneoplastic cells within and surrounding an IDH1mut glioma to D2HG is unknown and difficult to measure directly. Methods. Conditioned medium from patient-derived wild type IDH1 (IDH1wt) and IDH1mut glioma cells was analyzed for D2HG by liquid chromatography-mass spectrometry (LC-MS). Mathematical models of D2HG release and diffusion around an IDH1mut glioma were independently generated based on fluid dynamics within the brain and on previously reported intratumoral and cerebrospinal D2HG concentrations. Results. LC-MS analysis indicates that patient-derived IDH1mut glioma cells release 3.7-97.0 pg D2HG per cell per week. Extrapolating this to an average-sized tumor (30 mL glioma volume and 1 × 108 cells/mL tumor), the rate of D2HG release by an IDH1mut glioma (SA) is estimated at 3.2-83.0 × 10−12 mol/mL/sec. Mathematical models estimate an SA of 2.9-12.9 × 10−12 mol/mL/sec, within the range of the in vitro LC-MS data. In even the most conservative of these models, the extracellular concentration of D2HG exceeds 3 mM within a 2 cm radius from the center of an IDH1mut glioma. Conclusions. The microenvironment of an IDH1mut glioma is likely being exposed to high concentrations of D2HG, in the low millimolar range. This has implications for understanding how D2HG affects nonneoplastic cells in an IDH1mut glioma.

Original languageEnglish (US)
Pages (from-to)1197-1206
Number of pages10
JournalNeuro-Oncology
Volume20
Issue number9
DOIs
StatePublished - Jan 1 2018

Fingerprint

Glioma
Central Nervous System
Liquid Chromatography
Mass Spectrometry
alpha-hydroxyglutarate
Theoretical Models
Isocitrate Dehydrogenase
Hydrodynamics
Conditioned Culture Medium
Point Mutation
Cerebrospinal Fluid
Neoplasms

Keywords

  • D-2-hydroxyglutarate
  • Glioma
  • IDH1
  • Mathematical modeling
  • Microenvironment

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Linninger, A., Hartung, G. A., Liu, B. P., Mirkov, S., Tangen, K., Lukas, R. V., ... Horbinski, C. (2018). Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. Neuro-Oncology, 20(9), 1197-1206. https://doi.org/10.1093/neuonc/noy051

Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. / Linninger, Andreas; Hartung, Grant A.; Liu, Benjamin P.; Mirkov, Snezana; Tangen, Kevin; Lukas, Rimas V.; Unruh, Dusten; David James, C.; Sarkaria, Jann N; Horbinski, Craig.

In: Neuro-Oncology, Vol. 20, No. 9, 01.01.2018, p. 1197-1206.

Research output: Contribution to journalArticle

Linninger, A, Hartung, GA, Liu, BP, Mirkov, S, Tangen, K, Lukas, RV, Unruh, D, David James, C, Sarkaria, JN & Horbinski, C 2018, 'Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system', Neuro-Oncology, vol. 20, no. 9, pp. 1197-1206. https://doi.org/10.1093/neuonc/noy051
Linninger, Andreas ; Hartung, Grant A. ; Liu, Benjamin P. ; Mirkov, Snezana ; Tangen, Kevin ; Lukas, Rimas V. ; Unruh, Dusten ; David James, C. ; Sarkaria, Jann N ; Horbinski, Craig. / Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. In: Neuro-Oncology. 2018 ; Vol. 20, No. 9. pp. 1197-1206.
@article{148bc7d0e54b4a9198074eb82a72da8a,
title = "Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system",
abstract = "Background. Among diffusely infiltrative gliomas in adults, 20{\%}-30{\%} contain a point mutation in isocitrate dehydrogenase 1 (IDH1mut), which increases production of D-2-hydroxyglutarate (D2HG). This is so efficient that D2HG often reaches 30 mM within IDH1mut gliomas. Yet, while up to 100 µM D2HG can be detected in the circulating cerebrospinal fluid of IDH1mut glioma patients, the exposure of nonneoplastic cells within and surrounding an IDH1mut glioma to D2HG is unknown and difficult to measure directly. Methods. Conditioned medium from patient-derived wild type IDH1 (IDH1wt) and IDH1mut glioma cells was analyzed for D2HG by liquid chromatography-mass spectrometry (LC-MS). Mathematical models of D2HG release and diffusion around an IDH1mut glioma were independently generated based on fluid dynamics within the brain and on previously reported intratumoral and cerebrospinal D2HG concentrations. Results. LC-MS analysis indicates that patient-derived IDH1mut glioma cells release 3.7-97.0 pg D2HG per cell per week. Extrapolating this to an average-sized tumor (30 mL glioma volume and 1 × 108 cells/mL tumor), the rate of D2HG release by an IDH1mut glioma (SA) is estimated at 3.2-83.0 × 10−12 mol/mL/sec. Mathematical models estimate an SA of 2.9-12.9 × 10−12 mol/mL/sec, within the range of the in vitro LC-MS data. In even the most conservative of these models, the extracellular concentration of D2HG exceeds 3 mM within a 2 cm radius from the center of an IDH1mut glioma. Conclusions. The microenvironment of an IDH1mut glioma is likely being exposed to high concentrations of D2HG, in the low millimolar range. This has implications for understanding how D2HG affects nonneoplastic cells in an IDH1mut glioma.",
keywords = "D-2-hydroxyglutarate, Glioma, IDH1, Mathematical modeling, Microenvironment",
author = "Andreas Linninger and Hartung, {Grant A.} and Liu, {Benjamin P.} and Snezana Mirkov and Kevin Tangen and Lukas, {Rimas V.} and Dusten Unruh and {David James}, C. and Sarkaria, {Jann N} and Craig Horbinski",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/neuonc/noy051",
language = "English (US)",
volume = "20",
pages = "1197--1206",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system

AU - Linninger, Andreas

AU - Hartung, Grant A.

AU - Liu, Benjamin P.

AU - Mirkov, Snezana

AU - Tangen, Kevin

AU - Lukas, Rimas V.

AU - Unruh, Dusten

AU - David James, C.

AU - Sarkaria, Jann N

AU - Horbinski, Craig

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background. Among diffusely infiltrative gliomas in adults, 20%-30% contain a point mutation in isocitrate dehydrogenase 1 (IDH1mut), which increases production of D-2-hydroxyglutarate (D2HG). This is so efficient that D2HG often reaches 30 mM within IDH1mut gliomas. Yet, while up to 100 µM D2HG can be detected in the circulating cerebrospinal fluid of IDH1mut glioma patients, the exposure of nonneoplastic cells within and surrounding an IDH1mut glioma to D2HG is unknown and difficult to measure directly. Methods. Conditioned medium from patient-derived wild type IDH1 (IDH1wt) and IDH1mut glioma cells was analyzed for D2HG by liquid chromatography-mass spectrometry (LC-MS). Mathematical models of D2HG release and diffusion around an IDH1mut glioma were independently generated based on fluid dynamics within the brain and on previously reported intratumoral and cerebrospinal D2HG concentrations. Results. LC-MS analysis indicates that patient-derived IDH1mut glioma cells release 3.7-97.0 pg D2HG per cell per week. Extrapolating this to an average-sized tumor (30 mL glioma volume and 1 × 108 cells/mL tumor), the rate of D2HG release by an IDH1mut glioma (SA) is estimated at 3.2-83.0 × 10−12 mol/mL/sec. Mathematical models estimate an SA of 2.9-12.9 × 10−12 mol/mL/sec, within the range of the in vitro LC-MS data. In even the most conservative of these models, the extracellular concentration of D2HG exceeds 3 mM within a 2 cm radius from the center of an IDH1mut glioma. Conclusions. The microenvironment of an IDH1mut glioma is likely being exposed to high concentrations of D2HG, in the low millimolar range. This has implications for understanding how D2HG affects nonneoplastic cells in an IDH1mut glioma.

AB - Background. Among diffusely infiltrative gliomas in adults, 20%-30% contain a point mutation in isocitrate dehydrogenase 1 (IDH1mut), which increases production of D-2-hydroxyglutarate (D2HG). This is so efficient that D2HG often reaches 30 mM within IDH1mut gliomas. Yet, while up to 100 µM D2HG can be detected in the circulating cerebrospinal fluid of IDH1mut glioma patients, the exposure of nonneoplastic cells within and surrounding an IDH1mut glioma to D2HG is unknown and difficult to measure directly. Methods. Conditioned medium from patient-derived wild type IDH1 (IDH1wt) and IDH1mut glioma cells was analyzed for D2HG by liquid chromatography-mass spectrometry (LC-MS). Mathematical models of D2HG release and diffusion around an IDH1mut glioma were independently generated based on fluid dynamics within the brain and on previously reported intratumoral and cerebrospinal D2HG concentrations. Results. LC-MS analysis indicates that patient-derived IDH1mut glioma cells release 3.7-97.0 pg D2HG per cell per week. Extrapolating this to an average-sized tumor (30 mL glioma volume and 1 × 108 cells/mL tumor), the rate of D2HG release by an IDH1mut glioma (SA) is estimated at 3.2-83.0 × 10−12 mol/mL/sec. Mathematical models estimate an SA of 2.9-12.9 × 10−12 mol/mL/sec, within the range of the in vitro LC-MS data. In even the most conservative of these models, the extracellular concentration of D2HG exceeds 3 mM within a 2 cm radius from the center of an IDH1mut glioma. Conclusions. The microenvironment of an IDH1mut glioma is likely being exposed to high concentrations of D2HG, in the low millimolar range. This has implications for understanding how D2HG affects nonneoplastic cells in an IDH1mut glioma.

KW - D-2-hydroxyglutarate

KW - Glioma

KW - IDH1

KW - Mathematical modeling

KW - Microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85055432451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055432451&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noy051

DO - 10.1093/neuonc/noy051

M3 - Article

VL - 20

SP - 1197

EP - 1206

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 9

ER -